Jennifer Green, MD, professor of medicine at Duke University School of Medicine, member of Duke Clinical Research Institute, and EMPA-KIDNEY collaborator, discussed findings of the EMPA-KIDNEY trial presented at Kidney Week 2022, which showed a 28% improvement for patients with chronic kidney disease (CKD) on empagliflozin, whether in reduced mortality from cardiovascular disease or progression of CKD.
Watch
Dr Brent W. Miller on Emerging Technologies in Home Dialysis and Strategies to Improve Uptake
November 4th 2022Brent W. Miller, MD, board certified nephrologist and professor of clinical medicine at Indiana University School of Medicine, discussed new and emerging technologies for at-home hemodialysis and peritoneal dialysis, as well as efforts that have been made to address uptake issues for patients with kidney disease.
Watch
Pfizer’s updated COVID-19 booster was found to be nearly 4 times more efficacious against Omicron in older adults; CDC released more flexible guidelines for clinicians prescribing opioids; Senator Mark Warner released a report offering solutions to cybersecurity threats to the health care sector.
Read More
Rheumatologists Grow More Comfortable With Biosimilars, but Concerns Remain
November 4th 2022Ahead of the big wave of adalimumab biosimilars launching in the US market in 2023, rheumatologists report growing confidence in using biosimilars but remain concerned about their efficacy and economic benefit.
Read More
Empagliflozin Cuts Risk of Cardiovascular Death, More Severe CKD by 28%, Study Finds
November 4th 2022Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, reduced the risk of death or worsening progression of chronic kidney disease (CKD) by 28%, according to results published Friday at Kidney Week 2022.
Read More
A poster presented at the Academy of Managed Care Pharmacy Nexus 2022 showed that patients with recurrent Clostridioides difficile infection (rCDI), who had Medicare Advantage Part D coverage or were enrolled in a commercial health plan were associated with significantly greater health care resource utilization, including emergency department and inpatient visits, compared with those without rCDI.
Read More
Dr Jason Ezra Hawkes Reviews Recent Advances, Unmet Needs in Management of Hidradenitis Suppurativa
November 4th 2022Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of Dermatology at the University of California Davis in Sacramento, spoke on challenges in the management of hidradenitis suppurativa (HS), as well as promising therapies in the pipeline that target specific pathways suggested to play a role in the pathogenesis and pathophysiology of the disease.
Watch
Macitentan Safety, Effectiveness in PAH Confirmed in New Analysis
November 3rd 2022Two data sets from patients with severe pulmonary arterial hypertension (PAH) show the benefits of macitentan (Opsumit) monotherapy despite guidelines calling for combination therapy, even among patients with World Health Organizational functional class I-II disease.
Read More
As Medical Falsehoods Persist, Concerns About Future Pandemic Readiness Grow
November 3rd 2022Physicians and scientists are worried about the future pandemic preparedness, and the reasons why are largely due to social and political influences, according to a keynote speech and panel discussion on the first day of Kidney Week 2022.
Read More
Change in Smoking Status and Subsequent BMI Change Linked to NAFLD Risk
November 3rd 2022Across 4 types of smoking status groups, nonalcoholic fatty liver disease (NAFLD) risk significantly increased among participants who saw an increase in body mass index (BMI) and decreased among participants whose BMI went down.
Read More
Glomerular Filtration Rate Based on Cystatin C More Accurate for Predicting CVD, Mortality
November 3rd 2022A prospective population-based cohort study found that glomerular filtration rate based on cystatin C was more sensitive and specific for cardiovascular disease (CVD) and mortality risks compared with glomerular filtration rate based on creatinine.
Read More
The HHS renewed the national public health emergency for the monkeypox outbreak in the United States; more demand for amoxicillin has led to a nationwide shortage as respiratory illnesses continue to spread; a drug already approved for weight loss in adults has demonstrated promise in teenagers aged 12 to 17 years.
Read More
FDA advisers met to discuss alternatives to the infrared light used in pulse oximeters, which can be absorbed by melanin; FDA warns of a national shortage of tracheostomy tubes, especially for pediatric patients; 1 in 5 deaths among adults aged between 20 and 49 years is due to excessive drinking.
Read More
Intermediate Parkinson Disease Associated With Significant Clinical, Economic Burden
November 2nd 2022A poster presented at Academy of Managed Care Pharmacy Nexus 2022 shows that patients with intermediate Parkinson disease place a significant resource burden on the US health care system in regard to treatment, emergency department visits, and admissions to rehabilitation centers.
Read More
Dr Neil Gross Discusses the Implications of pCR on Additional Treatment in Skin Cancer
November 2nd 2022Neil D. Gross, MD, FACS, head and neck surgeon and director of clinical research in the Department of Head and Neck Surgery at The University of Texas MD Anderson Cancer Center, discusses the results of study he and his team conducted in the setting of resectable stage II to IV cutaneous squamous cell carcinoma.
Watch